2 results match your criteria American journal of cancer therapy and pharmacology[Journal]

  • Page 1 of 1

The role of β-elimination for the clinical activity of hypomethylating agents and cyclophosphamide analogues.

Am J Cancer Ther Pharmacol 2016 19;3(1):1-8. Epub 2016 Sep 19.

University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD.

A beta-elimination reaction generally involves the cleavage of a sigma (σ) bond at the position beta (β) to a pair of electrons that departs a molecule via a nucleophilic leaving group, subsequently leading to the formation of a new pi (π) bond. We describe the importance of β-elimination reactions in the mechanisms of action of two classes of chemotherapeutic agents. First, we evaluate the chemical steps resulting in formation of 5-methyl-cytosine and its disassociation from DNA methytransferase (DNMT) by β-elimination reaction. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217992PMC
September 2016
3 Reads

A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

Am J Cancer Ther Pharmacol 2014 Sep;2(1):21-32

Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, 21287, USA.

Background: Digoxin was found to inhibit prostate cancer (PCa) growth via the inhibition of HIF-1α synthesis in a mouse model. We hypothesized that a therapeutic dose of digoxin could inhibit human PCa growth and disease progression.

Methods: An open label, single arm pilot study was performed. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287984PMC
September 2014
24 Reads
  • Page 1 of 1